The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection
Abstract
In preclinical studies, MF59 adjuvant offered improved protection against influenza virus challenge and significantly reduced the viral load in the lungs of challenged mice. In humans, MF59 is a safe and potent vaccine adjuvant that has been licensed in more than 20 countries (Fluad [Novartis Vaccines and Diagnostics Inc., MA, USA]). The safety profile of an MF59-adjuvanted vaccine is well established through a large safety database. MF59 adjuvant has had a significant impact on the immunogenicity of influenza vaccines in the elderly and in adults who are chronically ill. MF59 has also been shown to have a significant impact on the immunogenicity of pandemic influenza vaccines. MF59 allows for broader cross-reactivity against viral strains not included in the vaccine. MF59 has been shown to be more potent for both antibody and T-cell responses than aluminum-based adjuvants. MF59 has broad potential to be used as a safe and effective vaccine adjuvant for a wide range of vaccine types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives
Ellouz, F., Adam, A., Ciorbaru, R., & Lederer, E. (1974) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(74)90458-6 · Cited by 1,019
Nod-like proteins in immunity, inflammation and disease
Fritz, J. H., Ferrero, R. L., Philpott, D. J., & Girardin, S. E. (2006) · Nature Immunology · doi:10.1038/ni1412 · Cited by 892
A universal vaccine for serogroup B meningococcus
Giuliani, M. M., Adu-Bobie, J., Comanducci, M., Aricò, B., Savino, S., Santini, L., Brunelli, B., Bambini, S., Biolchi, A., Capecchi, B., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603940103 · Cited by 727
Corey, L., Langenberg, A. G. M., Ashley, R., Sekulovich, R. E., Izu, A. E., Douglas, Jr., Handsfield, H. H., Warren, T., Marr, L., Tyring, S., et al. (1999) · JAMA · doi:10.1001/jama.282.4.331 · Cited by 490
Vaccine design : the subunit and adjuvant approach
Powell, M. F., Newman, M. J., & Burdman, J. R. (1995) · Plenum Press eBooks · Cited by 451
The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine
Podda, A. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00499-0 · Cited by 333
Allison, A. C., & Byars, N. E. (1986) · Journal of Immunological Methods · doi:10.1016/0022-1759(86)90402-3 · Cited by 315
Sensitization and Antibody Formation after Injection of Tubercle Bacilli and Paraffin Oil.
Freund, J., Casals, J., & Hosmer, E. P. (1937) · Experimental Biology and Medicine · doi:10.3181/00379727-37-9625 · Cited by 311
Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines
Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S., & Ganne, V (2002) · Expert Review of Vaccines · doi:10.1586/14760584.1.1.111 · Cited by 308
MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines
Ott, G., Barchfeld, G. L., Chernoff, D., Radhakrishnan, R., van Hoogevest, P., & Van Nest, G. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_10 · Cited by 298
Stephenson, I., Bugarini, R., Nicholson, K. G., Podda, A., Wood, J. M., Zambon, M. C., & Katz, J. M. (2005) · The Journal of Infectious Diseases · doi:10.1086/428948 · Cited by 285
Edelman, R. (1980) · Clinical Infectious Diseases · doi:10.1093/clinids/2.3.370 · Cited by 245
A Compendium of Vaccine Adjuvants and Excipients
Vogel, F. R., & Powell, M. F. (1995) · Pharmaceutical Biotechnology · doi:10.1007/978-1-4615-1823-5_7 · Cited by 217
Wack, A., Baudner, B. C., Hilbert, A. K., Manini, I., Nuti, S., Tavarini, S., Scheffczik, H., Ugozzoli, M., Singh, M., Kazzaz, J., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2007.11.054 · Cited by 195
Self-citationA Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy
Langenberg, A. G. M., Burke, R. L., Adair, S. F., Sekulovich, R., Tigges, M., Dekker, C. L., & Corey, L. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-12-199506150-00001 · Cited by 177
Minutello, M., Senatore, F., Cecchinelli, G., Bianchi, M., Andreani, T., Podda, A., & Crovari, P. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00185-6 · Cited by 173
Stephenson, I., Nicholson, K. G., Colegate, A., Podda, A., Wood, J., Ypma, E., & Zambon, M. (2003) · Vaccine · doi:10.1016/s0264-410x(02)00632-1 · Cited by 166
Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports
Strassburg, M. A., Greenland, S., Sorvillo, F. J., Lieb, L. E., & Habel, L. A. (1986) · Vaccine · doi:10.1016/s0264-410x(86)80002-0 · Cited by 154
Audran, R., Cachat, M., Lurati, F., Soé, S., Leroy, O. Y., Corradin, G., Druilhe, P., & Spertini, F. (2005) · Infection and Immunity · doi:10.1128/iai.73.12.8017-8026.2005 · Cited by 153
Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations
Atmar, R. L., Keitel, W., Patel, S. M., Katz, J. M., She, D., Sahly, H. M. E., Pompey, J. M., Cate, T. R., & Couch, R. B. (2006) · Clinical Infectious Diseases · doi:10.1086/508174 · Cited by 148
Ott, G., Barchfeld, G. L., & Nest, G. V. (1995) · Vaccine · doi:10.1016/0264-410x(95)00089-j · Cited by 147
Valensi, J. P., Carlson, J. R., & Nest, G. A. V. (1994) · The Journal of Immunology · doi:10.4049/jimmunol.153.9.4029 · Cited by 143
Gasparini, R., Pozzi, T., Montomoli, E., Fragapane, E., Senatore, F., Minutello, M., & Podda, A. (2001) · European Journal of Epidemiology · doi:10.1023/a:1017919305501 · Cited by 129
Banzhoff, A., Nacci, P., & Podda, A. (2003) · Gerontology · doi:10.1159/000069172 · Cited by 129
Vaccine adjuvants : preparation methods and research protocols
O’Hagan, D. T. (2000) · Humana Press eBooks · Cited by 124
Self-citationDistribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice
Dupuis, M. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00263-7 · Cited by 123
Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers
Mitchell, D. K., Holmes, S. J., BURKE, R. L., Duliege, A. M., & Adler, S. P. (2002) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200202000-00009 · Cited by 108
Heineman, T. C., Clements-Mann, M. L., Poland, G. A., Jacobson, R. M., Izu, A. E., Sakamoto, D., Eiden, J., Nest, G. A. V., & Hsu, H. H. (1999) · Vaccine · doi:10.1016/s0264-410x(99)00088-2 · Cited by 103
Traquina, P., Morandi, M., Contorni, M., & Nest, G. V. (1996) · The Journal of Infectious Diseases · doi:10.1093/infdis/174.6.1168 · Cited by 100
Use of CpG oligodeoxynucleotides as immunoprotective agents
Klinman, D. M. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.6.937 · Cited by 100
Singh, M., Ugozzoli, M., Kazzaz, J., Chesko, J., Soenawan, E., Mannucci, D., Titta, F., Contorni, M., Volpini, G., & Guidice, G. D. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.09.046 · Cited by 92
Cherpelis, S., Shrivastava, I., Gettie, A., Jin, X., Ho, D. D., Barnett, S. W., & Stamatatos, L. (2001) · Journal of Virology · doi:10.1128/jvi.75.3.1547-1550.2001 · Cited by 89
Puig‐Barberà, J., Díez‐Domingo, J., Pérez‐Hoyos, S., Belenguer‐Varea, Á., & Vidal, D. G. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.07.017 · Cited by 79
Vaccines with the MF59 Adjuvant Do Not Stimulate Antibody Responses against Squalene
Giudice, G. D., Fragapane, E., Bugarini, R., Hora, M., Henriksson, T., Palla, E., O’Hagan, D. T., Donnelly, J., Rappuoli, R., & Podda, A. (2006) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00191-06 · Cited by 78
Self-citationBernstein, D. I., Schleiss, M. R., Berencsi, K., Gönczöl, É., Dickey, M., Khoury, P., Cadoz, M., Méric, C., Zahradnik, J. M., Duliège, A., et al. (2002) · The Journal of Infectious Diseases · doi:10.1086/339003 · Cited by 77
Iob, A., Brianti, G., Zamparo, E., & Gallo, T. (2005) · Epidemiology and Infection · doi:10.1017/s0950268805003936 · Cited by 77
Potent immunogenicity of an HIV-1 gag–pol fusion DNA vaccine delivered by in vivo electroporation
Otten, G. R., Schaefer, M. E., Doe, B., Liu, H., Megede, J. Z., Donnelly, J., Rabussay, D., Barnett, S. W., & Ulmer, J. B. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.08.017 · Cited by 76
MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice
Higgins, D. A., Carlson, J. R., & Nest, G. V. (1996) · Vaccine · doi:10.1016/0264-410x(95)00240-2 · Cited by 74
Cunningham, C. K., Wara, D. W., Kang, M., Fenton, T., Hawkins, E., McNamara, J., MOFENSON, L. M., Duliège, A., Francis, D., McFarland, E. J., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/319215 · Cited by 74
Otten, G. R., Schaefer, M. E., Doe, B., Liu, H., Srivastava, I. K., Megede, J. Z., Kazzaz, J., Lian, Y., Singh, M., Ugozzoli, M., et al. (2005) · Journal of Virology · doi:10.1128/jvi.79.13.8189-8200.2005 · Cited by 72
Self-citationSafety and Immunogenicity of a Genetically Engineered Human Immunodeficiency Virus Vaccine
Wintsch, J., Chaignat, C., Braun, D. G., Jeannet, M., Stalder, H., Abrignani, S., Montagna, D., Clavijo, F., Moret, P., Dayer, J.-M., et al. (1991) · The Journal of Infectious Diseases · doi:10.1093/infdis/163.2.219 · Cited by 68
Baldo, V., Baldovin, T., Floreani, A., Carraro, A. M., & Trivello, R. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.02.045 · Cited by 67
Granoff, D. M., McHugh, Y. E., Raff, H. V., Mokatrin, A., & Nest, G. A. V. (1997) · Infection and Immunity · doi:10.1128/iai.65.5.1710-1715.1997 · Cited by 62
Comparison of three different influenza vaccines in institutionalised elderly
Baldo, V., Menegon, T., Bonello, C., Floreani, A., Trivello, R., & “Mariutto” Collaborative Group (2001) · Vaccine · doi:10.1016/s0264-410x(01)00060-3 · Cited by 61
Otten, G. R., Schaefer, M. E., Greer, C. E., Calderon-Cacia, M., Coit, D., Kazzaz, J., Medina-Selby, A., Selby, M., Singh, M., Ugozzoli, M., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.10.6087-6092.2003 · Cited by 61
Self-citationThe Influence Of Adjuvant On The Therapeutic Efficacy Of A Recombinant Genital Herpes Vaccine
Burke, R. L., Goldbeck, C., Ng, P., Stanberry, L. R., Ott, G. S., & Nest, G. V. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/170.5.1110 · Cited by 59
Direction of Research on Vaccination against Influenza—New Studies with Immunologic Adjuvants
SALK, J. E., Laurent, A. M., & Bailey, M. L. (1951) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.41.6.669 · Cited by 55
Cataldo, D. M., & Nest, G. V. (1997) · Vaccine · doi:10.1016/s0264-410x(97)00115-1 · Cited by 54
O’Hagan, D. T., Ugozzoli, M., Barackman, J. D., Singh, M., Kazzaz, J., Higgins, K. W., VanCott, T., & Ott, G. S. (2000) · Vaccine · doi:10.1016/s0264-410x(99)00522-8 · Cited by 46
Self-citationBaldo, V., Baldovin, T., Floreani, A., Fragapane, E., Trivello, R., & The Family Medicine Group (2007) · Journal of Clinical Immunology · doi:10.1007/s10875-007-9100-4 · Cited by 43
MF59: a safe and potent adjuvant for human use
Podda, A., Giudice, G. D., & O’Hagan, D. T. (2006) · Elsevier eBooks · doi:10.1016/b978-012088403-2/50010-1 · Cited by 31
Self-citation
Cited by
Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery
Kowalski, P. S., Rudra, A., Miao, L., & Anderson, D. G. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.012 · Cited by 1,127
Zhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Molecular and cellular signatures of human vaccine adjuvants
Mosca, F., Tritto, E., Muzzi, A., Monaci, E., Bagnoli, F., Iavarone, C., O'Hagan, D., Rappuoli, R., & De Gregorio, E. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804699105 · Cited by 492
Self-citationThe mechanism of action of MF59 – An innately attractive adjuvant formulation
O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.061 · Cited by 488
Self-citationLederer, K., Castaño, D., Gómez Atria, D., Oguin, T. H., Wang, S., Manzoni, T. B., Muramatsu, H., Hogan, M. J., Amanat, F., Cherubin, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.009 · Cited by 383
“A previously published study also described small GC formation by microscopy after one immunization with a protein antigen inMF59 (Liang et al., 2017).”
Influential
Metadata
- Authors
- O’Hagan, D. T.
- Venue
- Expert Review of Vaccines
- Publisher
- Informa UK Limited
- Published
- 2007-10-01
- Volume
- 6
- Issue
- 5
- Pages
- 699-710
- ISSN
- 1476-0584 (ISSN-L)
- 1744-8395
- OpenAlex
- W2067087090
- Cited by
- 282
- References
- 51
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.